RT Journal Article
SR Electronic
T1 Prognostic value of compact myocardial thinning in patients with left ventricular non-compaction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.19.24319385
DO 10.1101/2024.12.19.24319385
A1 Gegenava, Tea
A1 Tukker, Martijn
A1 Caliskan, Kadir
A1 Hirsch, Alexander
A1 Manohar, Ashish
A1 Lee, Seung-Pyo
A1 Owens, Anjali T.
A1 Kwon, Deborah H
A1 Ramchand, Jay
A1 Wheeler, Matthew T.
A1 Tang, W. H. Wilson
A1 Nieman, Koen
YR 2024
UL http://medrxiv.org/content/early/2024/12/22/2024.12.19.24319385.abstract
AB Introduction: Left ventricular non-compaction (LVNC) can be associated with a wide spectrum of clinical presentations, ranging from asymptomatic to ventricular tachyarrhythmia (VT), heart failure (HF), and cerebrovascular accidents (CVA). In this multicenter study, we explored the associations between clinical and imaging characteristics and outcomes of patients with LVNC, and externally validated the predictive value of myocardial thinning identified on cardiac magnetic resonance imaging (CMR) as previously described. Methods: 214 adult patients (54% male, mean age 41±16 years) meeting the imaging criteria for LVNC were identified. Baseline clinical data, echocardiographic findings, and CMR characteristics were analyzed. Long-axis balanced steady-state free precession CMR sequences were used to assess myocardial thickness. Myocardial thinning was defined as a 50% or greater diameter reduction of the compacted myocardium compared to a contiguous segment. The primary endpoint was a composite of all-cause mortality, HF hospitalization, need of left ventricular assist device (LVAD) or heart transplant, cardiac resynchronization therapy (CRT), CVA/transient ischemic attacks (TIA), and VT and appropriate implantable cardioverter defibrillator (ICD) therapy. Results: Focal myocardial thinning was observed in 42 patients (20%). Over a median follow-up period of 7 years (IQR, 4-10 years), 54 patients (24%) experienced a primary outcome (including all-cause mortality n=15 (7%), HF hospitalization/CRT n=33 (15%), CVA/TIA n=10 (5%), VT and appropriate ICD therapy n=14 (7%), LVAD/heart transplant n=3 (1.4%). Patients with myocardial thinning had more cumulative adverse events compared to those without myocardial thinning (chi-square = 29.516, log-rank < 0.001), even after matching for medical risk score. In a multivariate Cox regression model, myocardial thinning remained associated with outcomes: HR 3.052(95% CI: 1.569-5.937, p=0.001). When evaluating the incremental prognostic value of myocardial thinning over clinical and imaging characteristics, we observed that adding myocardial thinning added value to prediction models that included clinical and imaging features. Conclusions: The presence of myocardial thinning is associated with adverse cardiovascular events in adult LVNC patients. Along with the medical risk score and other imaging variables, this feature enhances the risk stratification of individuals with LVNC. Incorporating myocardial thinning into medical risk assessments can improve the prediction and management of adverse outcomes in these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards at both centers (Stanford: Pro00042745; Erasmus MC Ethics Committee: MEC-2024-0155)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be available upon request